-
1
-
-
0036780251
-
Clinical translation of angiogenesis inhibitors
-
Review
-
Kerbel R, Folkman J (2002) Clinical translation of angiogenesis inhibitors. Nat Rev Cancer. 2(10): 727-739. Review.
-
(2002)
Nat Rev Cancer
, vol.2
, Issue.10
, pp. 727-739
-
-
Kerbel, R.1
Folkman, J.2
-
2
-
-
30744449235
-
Angiogenesis as a therapeutic target
-
15
-
Ferrara N, Kerbel RS (2005) Angiogenesis as a therapeutic target. Nature.15;438(7070):967-974.
-
(2005)
Nature
, vol.438
, Issue.7070
, pp. 967-974
-
-
Ferrara, N.1
Kerbel, R.S.2
-
3
-
-
43249095919
-
Tumor angiogenesis
-
8
-
Kerbel RS (2008) Tumor angiogenesis. N Engl J Med 8;358(19):2039-2049.
-
(2008)
N Engl J Med
, vol.358
, Issue.19
, pp. 2039-2049
-
-
Kerbel, R.S.1
-
4
-
-
2442621619
-
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
-
Ferrara N, Hillan KJ, Gerber HP, Novotny W (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3: 391-400.
-
(2004)
Nat Rev Drug Discov
, vol.3
, pp. 391-400
-
-
Ferrara, N.1
Hillan, K.J.2
Gerber, H.P.3
Novotny, W.4
-
5
-
-
2542561964
-
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
-
Hurwitz H, Fehrenbacher L, Novotny, Cartwright T, Hainsworth J, et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl Med 350: 2335-2340.
-
(2004)
N Engl Med
, vol.350
, pp. 2335-2340
-
-
Hurwitz, H.1
Fehrenbacher, L.2
Novotny3
Cartwright, T.4
Hainsworth, J.5
-
6
-
-
35548947467
-
Inhibition of angiogenesis in the treatment of non-small cell lung cancer
-
Keedy VL, Sandler AB (2007) Inhibition of angiogenesis in the treatment of non-small cell lung cancer. Cancer Sci 98(12):1825-1830.
-
(2007)
Cancer Sci
, vol.98
, Issue.12
, pp. 1825-1830
-
-
Keedy, V.L.1
Sandler, A.B.2
-
7
-
-
33644833910
-
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma
-
Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, et al. (2006) Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24(1):16-24.
-
(2006)
J Clin Oncol
, vol.24
, Issue.1
, pp. 16-24
-
-
Motzer, R.J.1
Michaelson, M.D.2
Redman, B.G.3
Hudes, G.R.4
Wilding, G.5
-
8
-
-
33846148701
-
Sorafenib in advanced clear-cell renal-cell carcinoma
-
Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, et al. (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356(2): 125-134.
-
(2007)
N Engl J Med
, vol.356
, Issue.2
, pp. 125-134
-
-
Escudier, B.1
Eisen, T.2
Stadler, W.M.3
Szczylik, C.4
Oudard, S.5
-
9
-
-
27644436870
-
Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity
-
Shaked Y, Emmenegger U, Man S, Cervi D, Bertolini F, et al. (2005) Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity. Blood 106: 3058-3061.
-
(2005)
Blood
, vol.106
, pp. 3058-3061
-
-
Shaked, Y.1
Emmenegger, U.2
Man, S.3
Cervi, D.4
Bertolini, F.5
-
10
-
-
0041589524
-
Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells
-
Bertolini F, Paul S, Mancuso P, Monestiroli S, Gobbi A, et al. (2003) Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 63: 4342-4346.
-
(2003)
Cancer Res
, vol.63
, pp. 4342-4346
-
-
Bertolini, F.1
Paul, S.2
Mancuso, P.3
Monestiroli, S.4
Gobbi, A.5
-
11
-
-
33344459620
-
Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer
-
Fürstenberger G, von Moos R, Lucas R, Thürlimann B, Senn HJ, et al. (2006) Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer. Br J Cancer 94: 524-531.
-
(2006)
Br J Cancer
, vol.94
, pp. 524-531
-
-
Fürstenberger, G.1
Von Moos, R.2
Lucas, R.3
Thürlimann, B.4
Senn, H.J.5
-
12
-
-
13844255218
-
Circulating endothelial cells. Biomarker of vascular disease
-
Blann AD, Woywodt A, Bertolini F, Bull TM, Buyon JP, et al.2005) Circulating endothelial cells. Biomarker of vascular disease. Thromb Haemost 93: 228-235.
-
(2005)
Thromb Haemost
, vol.93
, pp. 228-235
-
-
Blann, A.D.1
Woywodt, A.2
Bertolini, F.3
Bull, T.M.4
Buyon, J.P.5
-
13
-
-
33746720071
-
Detection and quantification of mature circulating endothelial cells using flow cytometry and immunomagnetic beads: A methodological comparison
-
Goon PK, Boos CJ, Stonelake PS, Blann AD, Lip GY (2006) Detection and quantification of mature circulating endothelial cells using flow cytometry and immunomagnetic beads: A methodological comparison. Thromb Haemost 96: 45-52.
-
(2006)
Thromb Haemost
, vol.96
, pp. 45-52
-
-
Goon, P.K.1
Boos, C.J.2
Stonelake, P.S.3
Blann, A.D.4
Lip, G.Y.5
-
14
-
-
58849156504
-
Validation of a standardized method for enumerating circulating endothelial cells and progenitors: Flow cytometry and molecular and ultrastructural analyses
-
Mancuso P, Antoniotti P, Quarna J, Calleri A, Rabascio C, et al. (2009) Validation of a standardized method for enumerating circulating endothelial cells and progenitors: flow cytometry and molecular and ultrastructural analyses. Clin Cancer Res 5 (1): 267-273.
-
(2009)
Clin Cancer Res
, vol.5
, Issue.1
, pp. 267-273
-
-
Mancuso, P.1
Antoniotti, P.2
Quarna, J.3
Calleri, A.4
Rabascio, C.5
-
15
-
-
33745939679
-
Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy
-
15
-
Mancuso P, Colleoni M, Calleri A, Orlando L, Maisonneuve P, et al. (2006) Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood 15;108(2): 452-459.
-
(2006)
Blood
, vol.108
, Issue.2
, pp. 452-459
-
-
Mancuso, P.1
Colleoni, M.2
Calleri, A.3
Orlando, L.4
Maisonneuve, P.5
-
16
-
-
0942277099
-
Increased levels of viable circulating endothelial cells are an indicator of progressive disease in cancer patients
-
Beerepoot LV, Mehra N, Vermaat JS, Zonnenberg BA, Gebbink MF, et al. (2004) Increased levels of viable circulating endothelial cells are an indicator of progressive disease in cancer patients. Ann Oncol 15(1): 139-145.
-
(2004)
Ann Oncol
, vol.15
, Issue.1
, pp. 139-145
-
-
Beerepoot, L.V.1
Mehra, N.2
Vermaat, J.S.3
Zonnenberg, B.A.4
Gebbink, M.F.5
-
17
-
-
84867514583
-
Circulating endothelial cells and microparticles as prognostic markers in advanced non-small cell lung cancer
-
2012
-
Fleitas T, Martínez-Sales V, Vila V, Reganon E, Mesado D, et al. (2012) Circulating endothelial cells and microparticles as prognostic markers in advanced non-small cell lung cancer. PLoS One. 2012;7(10): e47365.
-
(2012)
PLoS One.
, vol.7
, Issue.10
, pp. e47365
-
-
Fleitas, T.1
Martínez-Sales, V.2
Vila, V.3
Reganon, E.4
Mesado, D.5
-
18
-
-
65649091778
-
Circulating endothelial cells in non-small cell lung cancer patients treated with carboplatin and paclitaxel
-
Kawaishi M, Fujiwara Y, Fukui T, Kato T, Yamada K, et al. (2009) Circulating endothelial cells in non-small cell lung cancer patients treated with carboplatin and paclitaxel. J Thorac Oncol 4(2): 208-213.
-
(2009)
J Thorac Oncol
, vol.4
, Issue.2
, pp. 208-213
-
-
Kawaishi, M.1
Fujiwara, Y.2
Fukui, T.3
Kato, T.4
Yamada, K.5
-
19
-
-
84869091543
-
Endothelial cell heterogeneity
-
Aird WC (2012) Endothelial cell heterogeneity. Cold Spring Harb Perspect Med 2(1):a006429. doi: 10.1101/cshperspect.a006429
-
(2012)
Cold Spring Harb Perspect Med
, vol.2
, Issue.1
, pp. a006429
-
-
Aird, W.C.1
-
20
-
-
0030855630
-
Heterogeneity of endothelial cells. Specific markers
-
Garlanda C, Dejana E (1997) Heterogeneity of endothelial cells. Specific markers Arterioscler Thromb Vasc Biol 17: 1193-1202.
-
(1997)
Arterioscler Thromb Vasc Biol
, vol.17
, pp. 1193-1202
-
-
Garlanda, C.1
Dejana, E.2
-
21
-
-
57749184341
-
Molecular heterogeneity of tumor endothelium
-
Aird WC (2009) Molecular heterogeneity of tumor endothelium. Cell Tissue Res 335(1): 271-281.
-
(2009)
Cell Tissue Res
, vol.335
, Issue.1
, pp. 271-281
-
-
Aird, W.C.1
-
22
-
-
0032528192
-
Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display
-
Rajotte D, Arap W, Hagedorn M, Koivunen E, Pasqualini R, et al. (1998) Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display. J Clin Invest 102: 430-437.
-
(1998)
J Clin Invest
, vol.102
, pp. 430-437
-
-
Rajotte, D.1
Arap, W.2
Hagedorn, M.3
Koivunen, E.4
Pasqualini, R.5
-
23
-
-
0034682892
-
Genes expressed in human tumor endothelium
-
St Croix B, Rago C, Velculescu V, Traverso G, Romans KE, et al. (2000) Genes expressed in human tumor endothelium. Science 289:1197-202.
-
(2000)
Science
, vol.289
, pp. 1197-1202
-
-
St Croix, B.1
Rago, C.2
Velculescu, V.3
Traverso, G.4
Romans, K.E.5
-
24
-
-
34249822498
-
Genes that distinguish physiological and pathological angiogenesis
-
Seaman S, Stevens J, Yang MY, Logsdon D, Graff-Cherry C, et al. (2007) Genes that distinguish physiological and pathological angiogenesis. Cancer Cell 11(6): 539-554.
-
(2007)
Cancer Cell
, vol.11
, Issue.6
, pp. 539-554
-
-
Seaman, S.1
Stevens, J.2
Yang, M.Y.3
Logsdon, D.4
Graff-Cherry, C.5
-
25
-
-
44349104675
-
Circulating endothelial cells in oncology: Pitfalls and promises
-
Strijbos MH, Gratama JW, Kraan J, Lamers CH, den Bakker MA, et al. (2008) Circulating endothelial cells in oncology: pitfalls and promises. Br J Cancer 98(11):1731-1735.
-
(2008)
Br J Cancer
, vol.98
, Issue.11
, pp. 1731-1735
-
-
Strijbos, M.H.1
Gratama, J.W.2
Kraan, J.3
Lamers, C.H.4
Den Bakker, M.A.5
-
26
-
-
84860460269
-
A new approach for rapid and reliable enumeration of circulating endothelial cells in patients
-
Kraan J, Strijbos MH, Sieuwerts AM, Foekens JA, den Bakker MA, et al. (2012) A new approach for rapid and reliable enumeration of circulating endothelial cells in patients. J Thromb Haemost 10(5): 931-939.
-
(2012)
J Thromb Haemost
, vol.10
, Issue.5
, pp. 931-939
-
-
Kraan, J.1
Strijbos, M.H.2
Sieuwerts, A.M.3
Foekens, J.A.4
Den Bakker, M.A.5
-
27
-
-
0036493793
-
Cell surface antigen CD109 is a novel member of the alpha(2) macroglobulin/C3, C4, C5 family of thioester-containing proteins
-
Lin M, Sutherland DR, Horsfall W, Totty N, Yeo E, et al. (2002) Cell surface antigen CD109 is a novel member of the alpha(2) macroglobulin/C3, C4, C5 family of thioester-containing proteins. Blood 99: 1683-1691.
-
(2002)
Blood
, vol.99
, pp. 1683-1691
-
-
Lin, M.1
Sutherland, D.R.2
Horsfall, W.3
Totty, N.4
Yeo, E.5
-
28
-
-
33845631481
-
Identification of CD109 as part of the TGF-beta receptor system in human keratinocytes
-
Finnson KW, Tam BY, Liu K, Marcoux A, Lepage P, et al. (2006) Identification of CD109 as part of the TGF-beta receptor system in human keratinocytes. FASEB 20: 1525-1527.
-
(2006)
FASEB
, vol.20
, pp. 1525-1527
-
-
Finnson, K.W.1
Tam, B.Y.2
Liu, K.3
Marcoux, A.4
Lepage, P.5
-
29
-
-
0032803285
-
CD109 is expressed on a subpopulation of CD34+ cells enriched in hematopoietic stem and progenitor cells
-
Murray LJ, Bruno E, Uchida N, Hoffman R, Nayar R, et al. (1999) CD109 is expressed on a subpopulation of CD34+ cells enriched in hematopoietic stem and progenitor cells. Experimental Hematology 27:8 1282-1294.
-
(1999)
Experimental Hematology
, vol.27
, Issue.8
, pp. 1282-1294
-
-
Murray, L.J.1
Bruno, E.2
Uchida, N.3
Hoffman, R.4
Nayar, R.5
-
30
-
-
0025962618
-
Identification of a cell-surface antigen associated with activated T lymphoblasts and activated platelets
-
Sutherland DR, Yeo E, Ryan A, Mills GB, Bailey D, et al. (1991) Identification of a cell-surface antigen associated with activated T lymphoblasts and activated platelets. Blood 77(1) 84-93.
-
(1991)
Blood
, vol.77
, Issue.1
, pp. 84-93
-
-
Sutherland, D.R.1
Yeo, E.2
Ryan, A.3
Mills, G.B.4
Bailey, D.5
-
31
-
-
0030695224
-
Immunologic phenotype of cultured endothelial cells: Quantitative analysis of cell surface molecules
-
Mutin M, Dignat-George F, Sampol J (1997) Immunologic phenotype of cultured endothelial cells: quantitative analysis of cell surface molecules. Tissue Antigens 50(5): 449-458.
-
(1997)
Tissue Antigens
, vol.50
, Issue.5
, pp. 449-458
-
-
Mutin, M.1
Dignat-George, F.2
Sampol, J.3
-
32
-
-
7244242362
-
Identification of a novel hierarchy of endothelial progenitor cells using human peripheral and umbilical cord blood
-
Ingram DA, Mead LE, Tanaka H, Meade V, Fenoglio A, et al. (2004) Identification of a novel hierarchy of endothelial progenitor cells using human peripheral and umbilical cord blood. Blood 104(9): 2752-2760.
-
(2004)
Blood
, vol.104
, Issue.9
, pp. 2752-2760
-
-
Ingram, D.A.1
Mead, L.E.2
Tanaka, H.3
Meade, V.4
Fenoglio, A.5
-
33
-
-
84864420793
-
Genome-wide identification of endothelial cell-enriched genes in the mouse embryo
-
Takase H, Matsumoto K, Yamadera R, Kubota Y, Otsu A, et al. (2012) Genome-wide identification of endothelial cell-enriched genes in the mouse embryo. Blood 120(4): 914-923.
-
(2012)
Blood
, vol.120
, Issue.4
, pp. 914-923
-
-
Takase, H.1
Matsumoto, K.2
Yamadera, R.3
Kubota, Y.4
Otsu, A.5
-
34
-
-
0141810332
-
Novel multiparameter flow cytometry assay using Syto16 for the simultaneous detection of early apoptosis and apoptosis-corrected P-glycoprotein function in clinical samples
-
van der Pol MA, Broxterman HJ, Westra G, Ossenkoppele GJ, Schuurhuis GJ (2003) Novel multiparameter flow cytometry assay using Syto16 for the simultaneous detection of early apoptosis and apoptosis-corrected P-glycoprotein function in clinical samples. Cytometry B Clin Cytom 55(1): 14-21.
-
(2003)
Cytometry B Clin Cytom
, vol.55
, Issue.1
, pp. 14-21
-
-
Van Der Pol, M.A.1
Broxterman, H.J.2
Westra, G.3
Ossenkoppele, G.J.4
Schuurhuis, G.J.5
-
35
-
-
33846798106
-
Phenotypic heterogeneity of the endothelium: I. Structure, function, and mechanisms
-
Aird WC (2007) Phenotypic heterogeneity of the endothelium: I. Structure, function, and mechanisms. Circ Res 100(2):158-173.
-
(2007)
Circ Res
, vol.100
, Issue.2
, pp. 158-173
-
-
Aird, W.C.1
-
36
-
-
54449099774
-
Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer
-
20
-
Dellapasqua S, Bertolini F, Bagnardi V, Campagnoli E, Scarano E, et al. (2008) Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J Clin Oncol 20;26(30): 4899-4905.
-
(2008)
J Clin Oncol
, vol.26
, Issue.30
, pp. 4899-4905
-
-
Dellapasqua, S.1
Bertolini, F.2
Bagnardi, V.3
Campagnoli, E.4
Scarano, E.5
-
37
-
-
73349127099
-
Predictive Potential of Angiogenic Growth Factors and Circulating Endothelial Cells in Breast Cancer Patients Receiving Metronomic Chemotherapy Plus Bevacizumab
-
Calleri A, Bono A, Bagnardi V, Quarna J, Mancuso P, et al. (2009) Predictive Potential of Angiogenic Growth Factors and Circulating Endothelial Cells in Breast Cancer Patients Receiving Metronomic Chemotherapy Plus Bevacizumab. Clin Cancer Res 15(24): 7652-7657.
-
(2009)
Clin Cancer Res
, vol.15
, Issue.24
, pp. 7652-7657
-
-
Calleri, A.1
Bono, A.2
Bagnardi, V.3
Quarna, J.4
Mancuso, P.5
-
38
-
-
33750286135
-
The multifaceted circulating endothelial cell in cancer: Towards marker and target identification
-
Bertolini F, Shaked Y, Mancuso P, Kerbel RS (2006) The multifaceted circulating endothelial cell in cancer: towards marker and target identification. Nat Rev Cancer 6(11):835-845.
-
(2006)
Nat Rev Cancer
, vol.6
, Issue.11
, pp. 835-845
-
-
Bertolini, F.1
Shaked, Y.2
Mancuso, P.3
Kerbel, R.S.4
-
39
-
-
33846149645
-
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients
-
Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, et al. (2007) AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11(1): 83-95.
-
(2007)
Cancer Cell
, vol.11
, Issue.1
, pp. 83-95
-
-
Batchelor, T.T.1
Sorensen, A.G.2
Di Tomaso, E.3
Zhang, W.T.4
Duda, D.G.5
-
40
-
-
84884194253
-
Prognostic value of CD109+ circulating endothelial cells in recurrent glioblastomas treated with bevacizumab and irinotecan
-
12; eCollection 2013
-
Cuppini L, Calleri A, Bruzzone MG, Prodi E, Anghileri E, et al. (2013) Prognostic value of CD109+ circulating endothelial cells in recurrent glioblastomas treated with bevacizumab and irinotecan. PLoS One 12;8(9): e74345 doi: 10.1371/journal.pone.0074345. eCollection 2013.
-
(2013)
PLoS One
, vol.8
, Issue.9
, pp. e74345
-
-
Cuppini, L.1
Calleri, A.2
Bruzzone, M.G.3
Prodi, E.4
Anghileri, E.5
-
41
-
-
84901273142
-
Tumor endothelial markers define novel subsets of cancer-specific circulating endothelial cells associated with antitumor efficacy
-
Mehran R1, Nilsson M, Khajavi M, Du Z, Cascone T, et al. (2014) Tumor endothelial markers define novel subsets of cancer-specific circulating endothelial cells associated with antitumor efficacy Cancer Res. DOI: 10.1158/0008-5472.CAN-13-2044
-
(2014)
Cancer Res
-
-
Mehran, R.1
Nilsson, M.2
Khajavi, M.3
Du, Z.4
Cascone, T.5
-
42
-
-
84863012047
-
TEM8/ANTXR1 blockade inhibits pathological angiogenesis and potentiates tumoricidal responses against multiple cancer types
-
Chaudhary A, Hilton MB, Seaman S, Haines DC, Stevenson S, et al. (2012) TEM8/ANTXR1 blockade inhibits pathological angiogenesis and potentiates tumoricidal responses against multiple cancer types. Cancer Cell 21(2): 212-226.
-
(2012)
Cancer Cell
, vol.21
, Issue.2
, pp. 212-226
-
-
Chaudhary, A.1
Hilton, M.B.2
Seaman, S.3
Haines, D.C.4
Stevenson, S.5
-
43
-
-
68049120477
-
Host-derived tumor endothelial marker 8 promotes the growth of melanoma
-
Cullen M, Seaman S, Chaudhary A, Yang MY, Hilton MB, et al. (2009) Host-derived tumor endothelial marker 8 promotes the growth of melanoma. Cancer Res 69(15): 6021-6026.
-
(2009)
Cancer Res
, vol.69
, Issue.15
, pp. 6021-6026
-
-
Cullen, M.1
Seaman, S.2
Chaudhary, A.3
Yang, M.Y.4
Hilton, M.B.5
-
44
-
-
0035254206
-
CD13/APN is activated by angiogenic signals and is essential for capillary tube formation
-
Bhagwat SV, Lahdenranta J, Giordano R, Arap W, Pasqualini R, et al. (2001) CD13/APN is activated by angiogenic signals and is essential for capillary tube formation. Blood 97: 652-659
-
(2001)
Blood
, vol.97
, pp. 652-659
-
-
Bhagwat, S.V.1
Lahdenranta, J.2
Giordano, R.3
Arap, W.4
Pasqualini, R.5
|